MEREO BIOPHARMA GROUP

Company snapshot

MEREO BIOPHARMA GROUP is a biotech organization headquartered in LONDON, USA. It trades on NYSE under ticker MREO. Primary therapeutic focus areas include Solid Tumors, Pancreatic Cancer, Osteogenesis Imperfecta, Metastatic Colorectal Cancer, Ovarian Cancer. NovaPharmaNews links 47 clinical program(s), 0 drug profile(s), and 18 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (24), phase 2 (22), phase 3 (1).

• 47 active pipeline program(s) linked via ClinicalTrials.gov.
• 18 US patent(s) indexed to this assignee profile.
• 47 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for MEREO BIOPHARMA GROUP. Not investment advice.

• Peer + 0 momentum

  AbbVie Deutschland GmbH

  TA overlap score 40

• Peer + 0 momentum

  Cardiff Oncology

  TA overlap score 31.6

• Peer + 0 momentum

  RIGEL PHARMACEUTICALS

  TA overlap score 27.2

• Peer + 0 momentum

  Revolution Medicines

  TA overlap score 25.2

• Peer + 0 momentum

  Samsung Bioepis

  TA overlap score 24.8

• Peer + 0 momentum

  CASI Pharmaceuticals

  TA overlap score 24.4

• Peer + 0 momentum

  CNS Pharmaceuticals

  TA overlap score 24.2

• Peer + 0 momentum

  Kailera Therapeutics

  TA overlap score 23.4

• Peer + 0 momentum

  Zentalis Pharmaceuticals

  TA overlap score 22.8

• Peer + 0 momentum

  BeiGene

  TA overlap score 22.8

Recent activity

Latest pipeline, patent, and corporate events for MEREO BIOPHARMA GROUP.

1. Jun 8, 2026 Clinical update

   Vantictumab combined with paclitaxel — Phase 1

2. Jun 8, 2026 Clinical update

   Placebo Oral Tablet — Phase 2

3. Jun 8, 2026 Clinical update

   OMP-54F28, Paclitaxel and Carboplatin — Phase 1

4. Jun 8, 2026 Clinical update

   OMP-54F28, Nab-Paclitaxel and Gemcitabine — Phase 1

5. Jun 8, 2026 Clinical update

   Alvelestat (MPH966) — Phase 2

View all clinical trial activity →

• What is MEREO BIOPHARMA GROUP?

  MEREO BIOPHARMA GROUP is a biotech organization headquartered in LONDON, USA. It trades on NYSE under ticker MREO. Primary therapeutic focus areas include Solid Tumors, Pancreatic Cancer, Osteogenesis Imperfecta, Metastatic Colorectal Cancer, Ovarian Cancer. NovaPharmaNews links

• Is MEREO BIOPHARMA GROUP publicly traded?

  Yes. MEREO BIOPHARMA GROUP is listed with ticker MREO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does MEREO BIOPHARMA GROUP develop or market?

  We link 22 drug profile(s) where MEREO BIOPHARMA GROUP is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/mereo-biopharma-group-plc#company-drugs.

• What are the latest developments for MEREO BIOPHARMA GROUP?

  In the last 12 months our linked public records show 47 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does MEREO BIOPHARMA GROUP focus on?

  MEREO BIOPHARMA GROUP focuses on Solid Tumors, Pancreatic Cancer, Osteogenesis Imperfecta based on our analysis of their pipeline programs and drug development activities.